Here’s why Ozempic maker’s new weight-loss drug isn’t good enough for investors

New trial data showed CagriSema led to “superior” weight loss, but at a rate much less than original expectations of 25%.
Article Attribution | Read More at Article Source
The post Here’s why Ozempic maker’s new weight-loss drug isn’t good enough for investors appeared first on RocketNews.